{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:44:53Z","timestamp":1777085093712,"version":"3.51.4"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.2169\/internalmedicine.7599-21","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T22:10:32Z","timestamp":1628201432000},"page":"429-432","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous Immunoglobulin in the Treatment of Adalimumab-associated Optic Neuritis"],"prefix":"10.2169","volume":"61","author":[{"given":"Naohiro","family":"Uchio","sequence":"first","affiliation":[{"name":"Department of Neurology, Mitsui Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Yashita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitsui Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitsui Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Japan"},{"name":"Department of Neurology, National Hospital Organization Yonezawa National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitsui Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kunchok A, Aksamit AJ, Davis JM, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol 77: 937-946, 2020.","DOI":"10.1001\/jamaneurol.2020.1162"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Seror R, Richez C, Sordet C, et al. Concise report pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey. Rheumatol 52: 868-874, 2013.","DOI":"10.1093\/rheumatology\/kes375"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chung JH, Van Stavern, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci 244: 133-136, 2006.","DOI":"10.1016\/j.jns.2006.01.012"},{"key":"4","unstructured":"4. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol 34: 239-240, 2007."},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica 222: 292-294, 2008.","DOI":"10.1159\/000140257"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18: 475-481, 2010.","DOI":"10.3109\/09273948.2010.495814"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthal Inflamm Infect 2: 145-147, 2012.","DOI":"10.1007\/s12348-011-0058-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy : a prospective imaging and electrophysiological study. Arthritis Res Ther 16: R125, 2014.","DOI":"10.1186\/ar4582"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bru\u00e8 C, Mariotti C, Saitta A. Demyelinizing neurological disease after treatment with tumor necrosis factor-\u03b1 antagonists. Case Rep Ophthalmol 7: 345-353, 2016.","DOI":"10.1159\/000447086"},{"key":"10","unstructured":"10. Ichikawa K, Kobayashi H, Funaki T, Suzuki Y, Murakami A. A case of optic neuritis caused by adalimumab for ulcerative colitis. Neuroophthalmol Jpn 33: 254-258, 2016."},{"key":"11","unstructured":"11. Nakao S, Yamada Y, Ueno M, Kitaoka T. A case of optic neuritis under adalimumab therapy. Neuroophthalmol Jpn 33: 249-253, 2016."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol 9: 60-64, 2017.","DOI":"10.1159\/000461572"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Komandur A, Macintosh P, Moss H. Acute inflammatory optic neuritis associated with a self-taper of oral prednisone in a patient taking adalimumab. Neuroophthalmol 44: 186-189, 2020.","DOI":"10.1080\/01658107.2019.1566386"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNF \u03b1 therapy: a case report. Mult Scler Relat Disord 26: 37-39, 2018.","DOI":"10.1016\/j.msard.2018.08.029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 299: 152-157, 2016.","DOI":"10.1016\/j.jneuroim.2016.09.007"},{"key":"16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS\/MRI Analysis Group null","year":"1999","unstructured":"16. The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS\/MRI Analysis Group. TNF neutralization in MS Results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465, 1999.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ishikawa H, Kezuka T, Shikishima K, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 126: 1385-1398, 2019.","DOI":"10.1016\/j.ophtha.2019.04.042"},{"key":"18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","volume":"64","author":"HG Roed","year":"2005","unstructured":"18. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64: 804-810, 2005.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mimura O, Ishikawa H, Kezuka T, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol 65: 122-132, 2021.","DOI":"10.1007\/s10384-020-00790-9"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_7599-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:07:55Z","timestamp":1715231275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_7599-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7599-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"article-number":"7599-21"}}